Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares IssuedShares OutstandingShares Outstanding
Ratios

Silence Therapeutics (SLN) EBIAT (2020 - 2025)

Silence Therapeutics' EBIAT history spans 6 years, with the latest figure at -$11.8 million for Q4 2025.

  • On a quarterly basis, EBIAT fell 195.58% to -$11.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$88.6 million, a 73.02% decrease, with the full-year FY2025 number at -$88.6 million, down 95.55% from a year prior.
  • EBIAT hit -$11.8 million in Q4 2025 for Silence Therapeutics, up from -$21.0 million in the prior quarter.
  • Over the last five years, EBIAT for SLN hit a ceiling of $12.3 million in Q4 2024 and a floor of -$39.2 million in Q3 2024.
  • Historically, EBIAT has averaged -$16.2 million across 5 years, with a median of -$16.0 million in 2021.
  • Biggest five-year swings in EBIAT: surged 166.23% in 2024 and later plummeted 1134.0% in 2025.
  • Tracing SLN's EBIAT over 5 years: stood at -$15.1 million in 2021, then decreased by 16.64% to -$17.7 million in 2022, then fell by 5.23% to -$18.6 million in 2023, then soared by 166.23% to $12.3 million in 2024, then plummeted by 195.58% to -$11.8 million in 2025.
  • Business Quant data shows EBIAT for SLN at -$11.8 million in Q4 2025, -$21.0 million in Q3 2025, and -$27.4 million in Q2 2025.